KR20230171941A - 급성 폐손상 및 폐섬유증의 급성 악화를 개선하기 위한 의약 조성물 - Google Patents

급성 폐손상 및 폐섬유증의 급성 악화를 개선하기 위한 의약 조성물 Download PDF

Info

Publication number
KR20230171941A
KR20230171941A KR1020237035872A KR20237035872A KR20230171941A KR 20230171941 A KR20230171941 A KR 20230171941A KR 1020237035872 A KR1020237035872 A KR 1020237035872A KR 20237035872 A KR20237035872 A KR 20237035872A KR 20230171941 A KR20230171941 A KR 20230171941A
Authority
KR
South Korea
Prior art keywords
chain variable
variable region
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237035872A
Other languages
English (en)
Korean (ko)
Inventor
에스테반 가바자
코리나 가바자
아이작 캔
Original Assignee
고쿠리츠다이가쿠호진 미에다이가쿠
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고쿠리츠다이가쿠호진 미에다이가쿠, 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 filed Critical 고쿠리츠다이가쿠호진 미에다이가쿠
Publication of KR20230171941A publication Critical patent/KR20230171941A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237035872A 2021-03-19 2022-03-18 급성 폐손상 및 폐섬유증의 급성 악화를 개선하기 위한 의약 조성물 Pending KR20230171941A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021046301 2021-03-19
JPJP-P-2021-046301 2021-03-19
JP2021173381 2021-10-22
JPJP-P-2021-173381 2021-10-22
PCT/JP2022/012823 WO2022196816A1 (ja) 2021-03-19 2022-03-18 急性肺障害および肺線維症の急性増悪を改善するための医薬組成物

Publications (1)

Publication Number Publication Date
KR20230171941A true KR20230171941A (ko) 2023-12-21

Family

ID=83320552

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237035872A Pending KR20230171941A (ko) 2021-03-19 2022-03-18 급성 폐손상 및 폐섬유증의 급성 악화를 개선하기 위한 의약 조성물

Country Status (8)

Country Link
US (1) US20260116957A1 (cg-RX-API-DMAC7.html)
EP (1) EP4310099A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2022196816A1 (cg-RX-API-DMAC7.html)
KR (1) KR20230171941A (cg-RX-API-DMAC7.html)
AU (1) AU2022239051A1 (cg-RX-API-DMAC7.html)
CA (1) CA3214262A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023010992A (cg-RX-API-DMAC7.html)
WO (1) WO2022196816A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116570716B (zh) * 2023-04-28 2025-05-16 水木星辰生物制药(深圳)有限公司 lncRNA LOC646762表达的抑制剂的应用和药物
CN117327147B (zh) * 2023-09-26 2024-05-10 广东海洋大学 一种抗急性肺损伤多肽及其应用
WO2026134246A1 (ja) * 2024-12-18 2026-06-25 国立大学法人三重大学 Corisin発現非ヒト動物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021126957A1 (en) 2019-12-17 2021-06-24 Mie University Methods and compositions for evaluating and treating fibrosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
WO2014089209A2 (en) * 2012-12-04 2014-06-12 Abbvie, Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins
LT3071597T (lt) * 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
JP6394441B2 (ja) * 2014-04-07 2018-09-26 株式会社デンソー 内燃機関の冷却装置
US10280223B2 (en) * 2014-07-09 2019-05-07 Nippon Zenyaku Kogyo Co., Ltd. Anti-canine PD-1 antibody or anti-canine PD-L1 antibody
EP3380521A1 (en) * 2015-11-24 2018-10-03 Eli Lilly and Company Combination therapy for cancer
WO2017214456A1 (en) * 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
EP3678717B1 (en) * 2017-09-04 2026-07-08 Wockhardt Limited Autoinjector with a needle cover
EP3629024A1 (en) * 2018-09-26 2020-04-01 Assistance Publique - Hôpitaux de Marseille Cd146 and uses thereof as a biomarker and as a therapeutic target in the diagnosis and treatment of fibrosis
EP3689373A1 (en) * 2019-01-30 2020-08-05 IDT Biologika GmbH Inactivated apxia, apxiia and apxiiia toxins
JP2021046301A (ja) 2019-09-19 2021-03-25 株式会社Screenホールディングス フィルムの剥離装置及び、フィルムの剥離方法
US11723926B2 (en) * 2019-09-27 2023-08-15 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof
JP2021173381A (ja) 2020-04-28 2021-11-01 トヨタ自動車株式会社 ファンカップリング装置の制御装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021126957A1 (en) 2019-12-17 2021-06-24 Mie University Methods and compositions for evaluating and treating fibrosis

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
[비특허문헌 1] 1 King, T. E., Jr., Pardo, A. & Selman, M. Idiopathic pulmonary fibrosis. Lancet 378, 1949-1961, doi: 10.1016/S0140-6736 (11)60052-4 (2011).
[비특허문헌 10] Ley, B., Collard, H. R. & King, T. E., Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183, 431-440, doi: 10.1164/rccm.201006-0894CI (2011).
[비특허문헌 11] Dickson, R. P. et al. Radiographic Honeycombing and Altered Lung Microbiota in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med200, 1544-1547, doi: 10.1164/rccm.201903-0680LE (2019).
[비특허문헌 12] Han, M. K. et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med 2, 548-556, doi: 10.1016/S2213-2600(14)70069-4 (2014).
[비특허문헌 13] Huang, Y. et al. Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 196, 208-219, doi: 10.1164/rccm.201607-15250C (2017).
[비특허문헌 14] Molyneaux, P. L. et al. Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 195, 1640-1650, doi:10.1164/rccm.201607-14080C (2017).
[비특허문헌 15] Takahashi, Y. et al. Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis. Respir Resl9, 34, doi:10.1186/sl2931-018-0736-9 (2018).
[비특허문헌 16] Wang, J. et al. Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-gamma. ERJ Open Res 3, doi: 10.1183/23120541.00008-2017 (2017).
[비특허문헌 17] Molyneaux, P. L. et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res 18, 29, doi: 10.1186/sl2931-017-0511-3 (2017).
[비특허문헌 18] Weng, D. et al. The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Mediators Inflamm 2019, 5160694, doi: 10.1155/2019/5160694 (2019).
[비특허문헌 19] D'Alessandro-Gabazza, C. N. et al. A Staphylococcus pro-apoptotic peptide induces acute exacerbation of pulmonary fibrosis. Nat Commun 11, 1539, doi: 10.1038/s41467-020-15344-3 (2020).
[비특허문헌 2] 2 Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med370, 2071-2082, doi: 10.1056/NEJMoal402584 (2014).
[비특허문헌 3] King, T. E., Jr., Noble, P. W. & Bradford, W. Z. Treatments for idiopathic pulmonary fibrosis. N Engl J Med 371, 783-784, doi: 10.1056/NEJMcl407776 (2014).
[비특허문헌 4] King, T. E., Jr. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370, 2083-2092, doi: 10.1056/NEJMoal402582 (2014).
[비특허문헌 5] 5 Lederer, D. J. & Martinez, F. J. Idiopathic Pulmonary Fibrosis. N Engl J Med 378, 1811-1823, doi: 10.1056/NEJMral705751 (2018).
[비특허문헌 6] 6 Sgalla, G., Biffi, A. & Richeldi, L. Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history. Respirology 21, 427-437, doi: 10.1111/resp.l2683 (2016).
[비특허문헌 7] Kreuter, M. et al. Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. Eur Respir J 55, doi: 10.1183/13993003.01760-2019(2020).
[비특허문헌 8] Collard, H. R. et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 194, 265-275, doi: 10.1164/rccm.201604-0801CI (2016).
[비특허문헌 9] Natsuizaka, M. et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 190, 773-779, doi: 10.1164/rccm.201403-05660C (2014).

Also Published As

Publication number Publication date
US20260116957A1 (en) 2026-04-30
EP4310099A1 (en) 2024-01-24
JPWO2022196816A1 (cg-RX-API-DMAC7.html) 2022-09-22
AU2022239051A9 (en) 2023-10-26
MX2023010992A (es) 2023-11-14
AU2022239051A1 (en) 2023-10-12
WO2022196816A1 (ja) 2022-09-22
CA3214262A1 (en) 2022-09-22
EP4310099A4 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
DK2580240T3 (en) S100A4 ANTIBODIES AND THERAPEUTIC APPLICATIONS THEREOF
US20260116957A1 (en) Pharmaceutical composition for ameliorating acute lung injury and acute worsening of pulmonary fibrosis
AU2016353552B2 (en) N-terminal epitopes in Amyloid beta and conformationally-selective antibodies thereto
CN115066435A (zh) 针对lilrb2的单域抗体
EP4213801A1 (en) Antigen-binding molecules that bind to porphyromonas gingivalis
EP2248826B1 (en) Antibody directed against pcrv
EP3374382A1 (en) Epitopes in amyloid beta and conformationally-selective antibodies thereto
WO2023079442A2 (en) Antigen-binding molecules that bind to porphyromonas gingivalis
KR20080113239A (ko) 녹농균의 외막 단백질 pa0427
US11485776B2 (en) Antibodies against infectious diseases
US10975131B2 (en) Factor H-Fc immunotheraphy
US9868784B2 (en) Antibodies against the S100P protein for the treatment and diagnosis of cancer
JPWO2009142086A1 (ja) マイコプラズマ感染症用ワクチン組成物
CN117425672A (zh) 用于改善急性肺损伤和肺纤维化急性加重的药物组合物
US20230357373A1 (en) Methods and compositions for evaluating and treating fibrosis
WO2023148894A1 (ja) 歯の再生治療のためのusag-1を標的分子とした中和抗体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231019

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250318

Comment text: Request for Examination of Application